Fair Access: Ethical Principles and Case Laws

1. Meaning of fair access

Fair access means ensuring that people can obtain essential medical treatments, biotechnology, genetic therapies, biological enhancements, and related healthcare services without unjust discrimination based on income, social status, disability, gender, geographical location, or genetic characteristics.

In integrated human biological engineering, fair access becomes especially important because advanced technologies—such as gene therapy, artificial organs, neural implants, and regenerative medicine—may be expensive, scarce, or available only to selected populations.

Fair access does not necessarily mean that every person must receive every technology immediately. It means that decisions about availability, affordability, eligibility, and allocation must be transparent, evidence-based, non-discriminatory, and consistent with legitimate medical and social priorities.

The ethical objective is to prevent scientific progress from becoming a privilege exclusively enjoyed by wealthy individuals while others are denied essential treatment.

2. Fundamental principles of fair access

A. Equality and non-discrimination

Access to biological engineering should not be determined by prejudice concerning disability, genetic traits, caste, sex, economic background, or social identity.

For example, a hospital should not deny an effective gene therapy to an eligible patient merely because the patient belongs to a disadvantaged community. Similarly, employers should not require expensive cognitive or physical enhancements as a condition of employment.

Equality does not require identical treatment in every circumstance. Individuals with greater medical needs may require additional support to achieve meaningful equality.

B. Affordability and economic justice

Advanced therapies may involve substantial research, manufacturing, and clinical costs. When treatments remain unaffordable, formally equal availability does not translate into actual access.

Ethical measures include public funding, insurance coverage, subsidies, differential pricing, transparent procurement, and lawful competition from generic or biosimilar products where available.

C. Fair allocation of scarce technologies

When a treatment is available only in limited quantities, allocation should follow clinically relevant criteria, such as urgency, expected benefit, medical suitability, and the likelihood of successful treatment.

Wealth, celebrity status, political influence, and social connections should not automatically confer priority.

D. Accessibility and inclusion

Fair access also requires suitable infrastructure, trained medical personnel, accessible facilities, and informed counselling. A therapy available only in major cities may remain inaccessible to rural communities.

For people with disabilities, access policies should respect personal autonomy and avoid treating disability itself as evidence of reduced social worth.

3. Important case laws on fair access

1. Paschim Banga Khet Mazdoor Samity v. State of West Bengal (1996)

Citation: (1996) 4 SCC 37, Supreme Court of India.

Facts: Hakim Sheikh, a seriously injured agricultural labourer, was taken to several government hospitals but was unable to obtain the necessary emergency treatment. He eventually received treatment at a private hospital.

Judgment: The Supreme Court held that failure by government hospitals to provide timely medical treatment in the circumstances violated Article 21 of the Constitution. It awarded compensation and directed measures to improve emergency medical services.

Indian Kanoon

+1

Relevance to fair access: The case establishes that access to essential medical care is not merely a question of individual purchasing power. The State has constitutional responsibilities to maintain adequate healthcare facilities.

Applied to biological engineering, this principle supports public policies that make essential gene therapies, advanced diagnostic services, and other life-preserving technologies reasonably accessible. It does not, however, establish an unconditional right to every experimental or enhancement technology.

2. State of Punjab v. Ram Lubhaya Bagga (1998)

Citation: (1998) 4 SCC 117, Supreme Court of India.

Facts: The dispute concerned the reimbursement of medical expenses incurred by government employees and pensioners for treatment at a private hospital.

Judgment: The Court recognized the State's obligation to protect health under Articles 21 and 47 but also accepted that healthcare policies may account for financial constraints, provided they remain constitutionally and legally valid.

Indian Kanoon

+1

Relevance to fair access: Fair access requires balancing individual healthcare needs against finite public resources. Governments may establish reimbursement limits and eligibility criteria, but such policies must not be arbitrary or unlawful.

For advanced biotechnology, this supports transparent decisions about which treatments should receive public funding, how much financial assistance should be provided, and which clinical indications should qualify.

3. Novartis AG v. Union of India (2013)

Citation: (2013) 6 SCC 1, Supreme Court of India.

Facts: Novartis sought patent protection for a particular crystalline form of imatinib mesylate, marketed as the cancer drug Glivec.

Judgment: The Supreme Court upheld the rejection of the patent application under Section 3(d) of the Patents Act, 1970, because the claimed product did not satisfy the statutory requirement concerning enhanced therapeutic efficacy.

Indian Kanoon

+1

Relevance to fair access: The case illustrates the relationship between patent law, pharmaceutical innovation, and public health. Patentability requirements can help prevent inappropriate extensions of monopoly protection and preserve opportunities for generic competition.

However, the judgment did not abolish pharmaceutical patents or establish that every expensive medicine must be made freely available. It applied a specific statutory patentability test.

4. Consumer Education and Research Centre v. Union of India (1995)

Citation: (1995) 3 SCC 42, Supreme Court of India.

Principle: The Supreme Court addressed workers' health, medical protection, and the relationship between health and the right to life under Article 21.

Relevance to fair access: The judgment reinforces the importance of protecting vulnerable populations from health risks. In biological engineering, this principle supports equitable access to necessary occupational healthcare and safeguards against exposing economically disadvantaged workers to biological risks without appropriate protection.

4. Application to integrated human biological engineering

A crucial distinction exists between therapeutic access and enhancement access. Treatment that prevents death or serious illness generally presents a stronger claim to public support than an elective modification intended to improve ordinary human abilities. The distinction is not absolute, and disability-related needs should not be dismissed merely because an intervention may also be described as enhancement.

5. Measures to promote fair access

Governments, healthcare institutions, and biotechnology companies can promote fairness through:

Public financing: Subsidize essential and clinically justified treatments for people who cannot afford them.

Transparent allocation: Publish eligibility criteria and provide procedures for reviewing disputed decisions.

Regional infrastructure: Expand specialist services beyond major urban hospitals.

Responsible intellectual-property policy: Apply patentability standards and lawful licensing mechanisms while maintaining incentives for genuine innovation.

Anti-discrimination safeguards: Prevent unjust exclusion based on genetic information, disability, or socioeconomic status.

Accountability: Monitor access disparities and provide effective complaint and redress mechanisms.

Conclusion

Fair access is a central ethical requirement of integrated human biological engineering because technological progress should not systematically benefit only wealthy or socially advantaged populations. The decisions in Paschim Banga Khet Mazdoor Samity, Ram Lubhaya Bagga, and Novartis v. Union of India demonstrate three complementary considerations: the State's healthcare obligations, the limits imposed by finite public resources, and the role of patent law in balancing innovation with public health.

The governing principle is that access decisions should be based on legitimate medical needs, scientific evidence, transparent allocation criteria, and constitutional equality—not wealth, prejudice, or social influence. Fair access does not promise every person every technology, but it requires a defensible and equitable system for deciding who receives available treatments and under what conditions.